INS and metabolic syndrome: These preclinical investigations have shown that after 4 weeks of supplementation, the new nutraceutical reduced fasting glycemia, insulin, HOMA-IR, HOMA-β, dyslipidemia, ectopic fat deposition, and hepatic fibrosis levels.